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Summary Hormone measurements during the menstrual cycle were assessed in six premenopausal women undergoing breast cancer
surgery and ten controls to determine whether the stress of diagnosis and surgery influenced cycle characteristics. There was hormonal
evidence for normal ovulation in all cancer and control women, although the length of the luteal phase of the cycle was prolonged because of
a delay in menstruation in two cancer patients. The timing of surgery in the cycle did not influence the hormonal data. The hormonal
characteristics of the menstrual cycle thus appear to be normally preserved in women during the month in which breast cancer surgery is
performed.
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When breast cancer is detected, women usually experience consid-
erable stress as investigation and surgical treatment proceeds.
Surprisingly little is known of the effect ofdiagnosis and surgery
for breast cancer on the characteristics of the menstrual cycle in
affected women, although it is clear that subsequent adjuvant
chemotherapy (Samaan et al, 1978) or endocrine therapy (Ravdin
et al, 1988; Yasumura et al, 1990) influence ovarian hormonal
secretion. There is currently considerable interest in the timing of
breast cancer surgery according to the phase of the menstrual
cycle, with the suggestion that overall survival is improved for
those having surgery in the luteal phase ofthe cycle (Badwe et al,
1991; Senie et al, 1991; Veronesi et al, 1994). Central to these
observations is the assumption that the characteristics ofthe cycle
remain normal at the time of diagnosis and surgery of a breast
tumour. The present study investigates the features of the
menstrual cycle in premenopausal women undergoing breast
cancer surgery.
MATERIALS AND METHODS
Blood samples were obtained from six women on days 5, 10, 12,
14, 16, 18, 20, 22, 24, 26 and 28 of the menstrual cycle in the
month in which surgery for primary breast cancer was performed,
defining day 1 as the first day of their menstrual period before
surgery. The timing of surgery was at the discretion of the patient
and surgeon and was carried out at various times during the cycle.
The mean time from first sign or symptom of breast cancer to
date of surgery was 28 days (range 13-86 days). Ten control
women were recruited by newspaper advertisement. In both
groups, blood sampling continued to day 28 or to the beginning
ofthe next period.
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Serum hormone assays
Oestradiol was determined by radioimmunoassay with sensitivity
S 19 pmol 1-', intra-assay coefficient of variation (CV) of 6% and
interassay CV of 9%. Progesterone was measured by radio-
immunoassay with sensitivity of 0.25 nmol l-', intra-assay CV of
3.6% and interassay CV of 8.5%. Plasma levels of luteinizing
hormone (LH) andfollicle-stimulating hormone (FSH) were deter-
mined by enzyme immunoassay with assay sensitivity of 0.8 IU
1-', intra-assay CV of 6% and interassay CV of 8.5% (LH) and
assay sensitivity of 0.8 IU 1-', intra-assay CV of 4.5% and
interassay CV of5% (FSH).
Ovulation was considered to have occurred ifa raised LH value
was observed followed by a progesterone value during the luteal
phase of the cycle exceeding 20 nmol 1-1. This definition was
based on observed luteal progesterone levels in conceptual
menstrual cycles ranging from 20-124 nmol 1-0 using the present
assay (France et al, 1992). The length of the luteal phase was
defined as the interval from the day ofthe maximum observed LH
value to the day before menstruation (normal 10-16 days; Lenton
et al, 1984). The length of the follicular phase was determined as
being from the first day of menstruation to the day of maximum
LH concentration.
Analysis of data
The day of the maximum observed LH value was defined as day
zero. Results from days -5 to -3, 0, 1-3, 4-6, and 7-10 were
grouped for analysis. Student's t-test was used to compare the
mean hormonal data in the cancer and control cases.
RESULTS
Hormone profiles
Controls and breast cancer subjects were almost exactly matched
for age, parity and regularity of periods. The mean values for
serum progesterone are shown in Figure 1 for cancer subjects and
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Figure 1 Concentration of serum progesterone in the luteal phase for breast cancer cases (n=5) and control cases (n=10)
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Figure 2 Mean value of serum luteinizing hormone, progesterone and oestrogen in cancer ( ) and control (----- ) cases
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controls. All subjects measured reached ovulatory levels of prog-
esterone. One cancer subject unfortunately mistimed the dates of
her cycle and luteal phase progesterone measurements were not
obtained. However, this individual had a normal ovulatory peak of
LH (19.3 IU 1-l). In one other cancer patient, sampling began on
day 12 of the cycle when progesterone values were already raised
(10.9 nmol 1-'), and no elevated LH value was detected; hence the
precise timing of the luteal phase could not be obtained. Her peak
progesterone level was 20.1 nmol 1-', indicating normal ovulation
but, because her progesterone levels could not be timed to a
maximum LH value, her data are not shown in Figure 1. The mean
values ofLH, progesterone and oestrogen forthe remaining cancer
and control cases grouped according to the maximum LH value are
shown in Figure 2. Results were similar in the two groups except
for a significantly lower mean maximum LH peak for cancer
subjects compared with controls (P = 0.04).
Cycle characteristics
Five of the six women with breast cancer had definite evidence of
ovulation with an LH peak followed by a progesterone peak > 20
nmol 1-', and the remaining woman had a maximum LH value of
19.3 IU 1-', indicating normal ovulation. All ten of the control
women had definite evidence of ovulation. Three women with
breast cancer had luteal phase lengths within the normal range of
10-16 days (10, 13 and 14 days). In two cancer patients, the luteal
phase was prolonged to 42 and 30 days, associated with maximum
progesterone levels of 22.2 and 58.6 nmol 1-' respectively.
Although serum progesterone had returmed to low levels by the
expected date in these individuals (Figure 1), the onset of menses
was delayed giving a total length of the menstrual cycle of 52 and
45 days respectively. In one woman with breast cancer the length
of the luteal phase could not be determined with accuracy as the
timing of the LH peak was uncertain, but her menstrual cycle
length in the month of surgery was 21 days (usual cycle length
21-39 days). All the control women had a luteal phase within the
normal range of 10-16 days. The follicular phase ofthe cycle was
similar in cancer patients (13 days) and controls (15 days).
Timing of surgery
Surgery was performed during the luteal phase ofthe cycle in four
women and during the follicular phase in two patients. The mean
length of the follicular phase was 13 days (range 12-15 days) for
those operated on in the luteal phase and 14 days (range 10-18
days) for those having follicular phase surgery. The mean length of
the luteal phase was 19 days (range 13-30 days) for those having
luteal phase surgery and 26 days (range 10-42 days) for those
having follicular phase surgery. The mean maximal serum LH
level was 9.8 IU 1-' for those having luteal phase surgery and 20.2
IU 1-' for those having follicular phase surgery.
DISCUSSION
It is known that the characteristics of the menstrual cycle in indi-
vidual women can be upset by environmental factors such as
departure from the parental home and stress (Metcalfe, 1983). It is,
however, unknown whether the stress of a new diagnosis ofbreast
cancer and undergoing mastectomy can also upset the normal
pattern of the female menstrual cycle. This is an issue of current
interest, as the observation that breast cancer prognosis is better in
those having surgery in the luteal rather than the follicularphase of
the cycle (Badwe et al, 1991; Senie et al, 1991; Veronesi et al,
1994) has been attributed to a protective effect of progesterone in
the second half of the cycle (Badwe et al, 1994). Clearly, if many
women undergoing breast cancer surgery had an abnormal cycle in
the month of surgery, the progesterone protection hypothesis
would be untenable.
The present study indicates that the hormonal characteristics of
the menstrual cycle are normally maintained in women recently
diagnosed with breast cancer and undergoing mastectomy. There
was evidence of a discreet LH surge in all subjects (except in one
patient with mistimed sampling), and there were normal ovulatory
levels of progesterone. The mean luteal phase progesterone level
was similar in the cancer patients (33.8 nmol 1-l) and in control
subjects (35.5 nmol 1-'), again supporting the view that ovulation
had proceeded normally in these individuals. The only identified
biochemical difference between controls and cancerpatients was a
lower maximum LH level in the cancer subjects of borderline
statistical significance. In view of the small numbers studied, and
in view of the 2-day spread of sampling times, it is possible that
the peak LH value may not always have been detected, and it is
unlikely that this difference is genuine. All ofthose with lower LH
levels had normal ovulatory progesterone responses, again
suggesting that the LH surge in these individuals was biologically
significant. Abnormal melatonin levels in breast cancer patients
(Holdaway et al, 1991) could, however, have reduced the LH
responsiveness to gonadotrophin-releasing hormone (GnRH)
(Fraser, 1980) in these individuals. Prolactin levels during the
cycle were normal (data not shown), with no suggestion that
stress-induced hyperprolactinaemia influenced LH production.
The present data indicate the generally robust nature of the
menstrual cycle, with preservation of normal hormonal character-
istics despite the stress ofbreast cancer diagnosis and surgery. The
delayed menstruation seen in two subjects may,however, represent
an effect of stress via as yet unknown mechanisms. The improved
prognosis in premenopausal women with breast cancer who
undergo tumour removal in the luteal phase of their cycle may be
related to a favourable hormonal milieu antagonizing tumour
dissemination at this time. The results ofthis study show that cycle
characteristics are normally preserved in these women and
provides general support for this hypothesis.
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